Nulojix 25 mg/ml
As listed in the register: Nulojix 25 mg/ml, poeder voor concentraat voor oplossing voor infusie
25 mg/ml · concentraat voor oplossing voor infusie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Belatacept
- Made by
- Bristol-Myers Squibb Pharma EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (NULOJIX). It describes the substance, not this exact product.
Belatacept, a selective T cell (lymphocyte) costimulation blocker, binds to CD80 and CD86 on antigen-presenting cells thereby blocking CD28 mediated costimulation of T lymphocytes.
In vitro, belatacept inhibits T lymphocyte proliferation and the production of the cytokines interleukin-2, interferon-γ, interleukin-4, and TNF-α.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2021-07-28
Safety of the active substance
From the US prescribing label for the same active substance (NULOJIX). It describes the substance, not this exact product.
WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).
- NULOJIX is contraindicated in transplant recipients who are Epstein-Barr virus (EBV) seronegative or with unknown EBV serostatus due to the risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS) [see Boxed Warning and Warnings and Precautions (5.1) ].
- Patients who are EBV seronegative or with unknown EBV serostatus.
Most common adverse reactions (≥20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Bristol-Myers Squibb Pharma EEIG |
|---|---|
| Active substance | Belatacept |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 25 mg/ml |
| Form | concentraat voor oplossing voor infusie |
| Classification | L04AA28 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Nulojix 25 mg/ml, poeder voor concentraat voor oplossing voor infusie |
| RVG | EU/1/11/694 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).